Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Lingohr Asset Management GmbH

Lingohr Asset Management GmbH trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 71.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,007 shares of the biotechnology company's stock after selling 22,986 shares during the period. Lingohr Asset Management GmbH's holdings in Exelixis were worth $304,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EXEL. Victory Capital Management Inc. boosted its position in shares of Exelixis by 16.6% in the third quarter. Victory Capital Management Inc. now owns 136,178 shares of the biotechnology company's stock worth $3,534,000 after acquiring an additional 19,372 shares during the last quarter. CIBC Asset Management Inc purchased a new position in Exelixis during the third quarter worth approximately $227,000. Natixis Advisors LLC boosted its holdings in shares of Exelixis by 26.2% in the 3rd quarter. Natixis Advisors LLC now owns 29,113 shares of the biotechnology company's stock valued at $755,000 after purchasing an additional 6,051 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Exelixis in the 3rd quarter valued at $1,972,000. Finally, Advisors Asset Management Inc. grew its stake in shares of Exelixis by 3.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company's stock valued at $515,000 after buying an additional 609 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Remove Ads

Exelixis Trading Up 2.1 %

NASDAQ EXEL traded up $0.76 during mid-day trading on Monday, reaching $37.72. 2,130,854 shares of the company's stock traded hands, compared to its average volume of 2,088,301. The company has a fifty day simple moving average of $35.66 and a 200-day simple moving average of $33.00. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The company has a market cap of $10.56 billion, a price-to-earnings ratio of 21.31, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the transaction, the director now owns 356,605 shares in the company, valued at approximately $13,479,669. This trade represents a 2.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares in the company, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 140,343 shares of company stock valued at $5,177,234. Insiders own 2.85% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on EXEL shares. Wells Fargo & Company cut Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price on the stock. in a report on Monday, February 24th. StockNews.com raised Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Oppenheimer downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. JMP Securities reaffirmed a "market outperform" rating and set a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. Finally, Citigroup increased their price objective on shares of Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.